AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline ...

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal

Eli Lilly and Co LLY on Thursday agreed to acquire AtaiBeckley Inc. ATAI in a deal that values the clinical-stage mental ...
The Manila Times

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target ...
The Daily Reflector

Calian and Atlantic Canadian partners form Canada's first integrated Arctic Maritime ...

Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic ...
BioSpace

AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

Banijay-All3Media: Is This the Last Great Super-Indie?

The world's largest independent production group has been created. Its next challenge is finding growth beyond the ...

U.S. House District 3 primary election voter's guide: Meet the candidates

Democrat Anna Golladay and Republican incumbent Chuck Fleischmann do not face primary challengers. Here's what they had to say.
Las Vegas Sun

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...

Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Dis…

Eisai Limited ("Eisai") and Biogen Canada Inc. are honoured to be one of the first countries in the world to receive a ...
BusinessMirror

4PH reaches Tarlac, 7K houses to rise

MORE than 7,000 affordable housing units are set to rise in Tarlac under the government’s Expanded Pambansang Pabahay para sa Pilipino (4PH) Program, adding to the pipeline of socialized housing ...

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA ® (enlicitide) tablets 20 mg as an adjunct ...
Rutland Herald

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug ...